Price
$87.84+17.12%Social Signal Score
Analyst Ratings
21 analystsRevenue
$339.38M+54.09%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christopher A. Simon
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 3,009
- Beta
- 0.54
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 3.11
Financials
Revenue
$339.38M+54.1%Net Income
$33.01M+66.5%EBITDA
$74.69M+57.2%Free Cash Flow
$44.42M+120.8%EPS (diluted)
$0.72+89.5%Shares Outstanding (diluted)
45.70M-11.6%Operating Expenses
$135.14MCash & Debt
$223.38MReturn of Capital
$3.50MRevenue by Segment (annual)
$2.14BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $1.33B | $97.31M | $2.05 |
| 2025 | $1.36B | $167.68M | $3.31 |
| 2024 | $1.31B | $117.56M | $2.32 |
| 2023 | $1.17B | $115.40M | $2.27 |
| 2022 | $993.20M | $43.38M | $0.85 |
| 2021 | $870.46M | $79.47M | $1.57 |
| 2020 | $988.48M | $76.53M | $1.51 |
| 2019 | $967.58M | $55.02M | $1.07 |
| 2018 | $903.92M | $45.57M | $0.86 |
| 2017 | $886.12M | $-26.27M | $-0.51 |
| 2016 | $908.83M | $-55.62M | $-1.09 |
| 2015 | $910.37M | $16.90M | $0.33 |
| 2014 | $938.51M | $35.15M | $0.68 |
| 2013 | $891.99M | $38.80M | $0.76 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from HAE's reported EPS growth of 7.9% a year over 13 years.
- EPS in 5 years
- $3.02
- Implied price
- $78.43
- Return from $104.68
- -5.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $38.99 — -62.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 18 | 22 | 26 | 30 | 34 |
|---|---|---|---|---|---|
| -2.1% | -20.4% | -17.2% | -14.4% | -11.9% | -9.6% |
| 2.9% | -16.4% | -12.9% | -10.0% | -7.4% | -5.0% |
| 7.9% | -12.3% | -8.7% | -5.6% | -2.9% | -0.4% |
| 12.9% | -8.2% | -4.5% | -1.2% | 1.6% | 4.2% |
| 17.9% | -4.2% | -0.3% | 3.1% | 6.1% | 8.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
60-14.29%Social Signal Score
Mentions (18)
- Newsglobenewswire.com·1d ago·Positive
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options
View source ↗ - Newsprnewswire.com·5d ago·Neutral
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026 BOSTON, Sept. 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, November 5, 2026.
View source ↗ - Newszacks.com·11d ago·Positive
Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - News (RSS)yahoo·17d ago·Neutral
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances
View source ↗ - Newsmarketbeat.com·17d ago·Negative
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances Intellia Therapeutics NASDAQ: NTLA executives outlined plans for a potential launch of its hereditary angioedema treatment, lonvo-z, while discussing the company's ongoing Phase III program in transthyretin amyloidosis and its capital position during a Morgan Stanley event.
View source ↗ - Newsglobenewswire.com·21d ago·Neutral
…26, as the first milestone payment in connection with the previously announced acquisition of Vivasure Medical Limited (“Vivasure”) by Haemonetics Corporation (NYSE: HAE, “Haemonetics”).
View source ↗ - Newszacks.com·26d ago·Negative
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
View source ↗ - Newsseekingalpha.com·38d ago·Neutral
BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve BioCryst Pharmaceuticals (BCRX) is evolving into a dual-product hereditary angioedema (HAE) franchise, targeting both oral and injectable prophylactic preferences. BCRX's ORLADEYO profit engine supports pipeline funding; Q2 2026 revenue reached $218.3M, with strong gross margins and positive cash flow independent of licensing receipts. The navenibart acquisition positions BCRX to capture injectable-preferring HAE patients, l…
View source ↗ - News (RSS)investing·41d ago·Negative
BioCryst gets Japan approval for HAE drug in young children
View source ↗ - Newsglobenewswire.com·42d ago·Neutral
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan — Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to
View source ↗ - News (RSS)seekingalpha·45d ago·Neutral
Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model
View source ↗ - Newsseekingalpha.com·46d ago·Negative
Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model Haemonetics is a medtech company that's increasingly generating more recurring revenues with plasma consumables. HAE also has MedSurg, which generates higher margins by selling technologies useful for cardiovascular procedures, for example. As such, these two segments give HAE a durable growth profile. And their recent agreement with CSL could expand on this potential.
View source ↗ - Newsgurufocus.com·48d ago·Neutral
Haemonetics Corp (HAE) Shares Surge 15.9% -- What GF Score of 85 Tells Investors On August 18, 2026, Haemonetics Corp (HAE) shares rose 15.9%, bringing the current price to $104.65. This performance reflects a significant 52-week range, with
View source ↗ - Newszacks.com·48d ago·Positive
Here's Why Haemonetics (HAE) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·49d ago·Positive
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy? The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newszacks.com·52d ago·Positive
HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasma growth and stronger cash generation.
View source ↗ - Newszacks.com·55d ago·Neutral
Haemonetics (HAE) Reliance on International Sales: What Investors Need to Know Examine Haemonetics' (HAE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
View source ↗ - Newsmarketbeat.com·59d ago·Positive
Haemonetics Q1 Earnings Call Highlights Haemonetics NYSE: HAE reported a stronger start to fiscal 2027, with first-quarter revenue rising 6% year over year to $339 million and adjusted diluted earnings per share increasing 4% to $1.14. The company raised its full-year revenue outlook, citing broad-based growth across its MedSurg and apheresis businesses, while maintaining a disciplined stance on assumptions for the remainder of the year.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $1.30 per share
Typical surprise +3.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$1.14 vs $1.08beat
- Thu, May 7$1.29 vs $1.28beat
- Thu, Feb 5$1.31 vs $1.27beat
- Thu, Nov 6$1.27 vs $1.12beat
- Thu, Aug 7$1.10 vs $1.01beat
- Thu, May 8$1.24 vs $1.22beat
Estimates and results for HAE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HAE officers and directors.
- Bought
- $99k
- Sold
- $592k
1 trade
3 trades
- Kroll Mark Wbought
- Strong Stewart Wsold
- Lingamneni Anilasold
- Lingamneni Anilasold
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Lois Frankelhouse · FL21 · disclosed May 25, 2021 (19d later)Sell$1,001 - $15,000
- Lois Frankelhouse · FL21 · disclosed May 25, 2021 (18d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Feb 9, 2021 (15d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 5, 2020 (20d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 13, 2020 (28d later)Sell$1,001 - $15,000
- Lois Frankelhouse · FL21 · disclosed Aug 24, 2020 (10d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 16, 2020 (15d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 16, 2020 (28d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jun 10, 2020 (26d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jun 10, 2020 (13d later)Buy$1,001 - $15,000
- Lois Frankelhouse · FL21 · disclosed Jun 22, 2018 (15d later)Sell$1,001 - $15,000
- Lois Frankelhouse · FL21 · disclosed Jun 22, 2018 (8d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.